Copenhagen-based SNIPR Biome, a CARB-X portfolio company, has developed SNIPR001, a cocktail of CRISPR-armed phages designed to target E. coli. A recent release by Robin Berghaus of CARB-X highlights the potential of SNIPR001 to prevent bloodstream infections in cancer patients without disrupting their microbiomes.